by Paul Fassa Health Impact News
Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S.
There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patients own stem cells, so no patent-able drugs are involved.
They are targetingthe most influential stem cell scientist in the U.S., Dr.Kristin Comella in Florida.
Many consider stem cell therapy the future of medicine. A stem cell can rebuild or create new cells in tissues, even in organ tissues other than those from which they had originally existed.
They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.
There is a considerable controversy surrounding stem cell therapy research, a branch ofregenerative medicine. Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.
Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.
Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patients own adipose tissue and inject them into areas where that same patient needs repair. Its an autologous process called adult stem cell therapy.
U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinics Chief Scientist isDr. Kristin Comella, PhD.
Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.
Dr. Kristin Comellaand her clinichave been under attack from theFDA.
This short 3-minute video was produced interviewing Dr. Comella and some of her patients.
Human embryonic stem cell (hESC) therapy has received most of the medias attention and government support. But it is the most controversial because it involves extracting tissues from terminated human embryos, aka aborted fetuses.
In addition to moral and ethical issues, human embryonic stem cell (hESC) solutions create cells so rapidly where theyre injected they lead to cancerous tumors. To avoid that, researchers have to use immuno-suppressant drugs to curb the embryonic stem cells tendency toward cancer.
Using pharmaceutical drugs to curb hESC cancer side effect issues leads to other unexplored and unexpected side effects from those patented stem cell solutions.
But the profit motive for embryonic stem cell therapies was strong and a lot of government funds had been put into its research. Pharmaceutical companies were motivated because they could patent stem cells created from embryonic tissues.
Bone marrow stem cell therapy was among the first to depart from flawed hESC (human embryonic stem cell) therapies developed over the past two decades.Bone marrow stem cell therapy was the segue into the adult stem cell therapy movement.
Bone marrow extractions are painful, requiring general anesthesia. Its relatively difficult and expensive compared to adipose (fat) tissue stem cell harvesting.
Bone marrows high white blood cell count also encourages inflammation, making it counter-productive for patients already suffering from chronic inflammation or autoimmune disorders.
Most importantly, adipose (fat) tissue yields up to 500 times more mesenchymal stem cells than bone marrow sources, according to Dr. Comella. These are potent stem cells that can differentiate into a wide variety of other cell types. Furthermore, the adipose white blood cell count is lower than bone marrow matter.
Overactive, confused immune responses attack organs continually and create chronic inflammation and autoimmune diseases. The lower white blood cell count automatically lowers the risk of further inflammation among patients already suffering from chronic inflammation and autoimmune diseases.
The outpatient treatment involves creating a very small and shallow incision that wont require stitches on an area of skin covering adipose tissue (fat). From there, liposuction can withdraw a portion of the fat. This part of the procedure requires only a local anesthetic.
Then what is extracted is spun at high speed in a special centrifuge to isolate the stem cells which are then purified for IV drip delivery or injection into the same patient from whom it was extracted. Total costs range from five to ten thousand dollars or more in some cases.
Dr. Comella and her colleagues mission is to get adult stem cell therapy available for everyone. Private and government health insurance providers cover medical treatments that are much more expensive.
Why not cover one that would save money with its lower expense and fewer side effects?
Over the years, there have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions as well as heart and lung issues.
But the three known adverse side effect cases continually get all the media attention.
The Panama College of Cell Science, which helped launch Kristin Comellas research and development, had this to say about her:
Perhaps the most influential clinician on the subject of adult stem cell therapy, Dr. Comella has been able to quietly develop patient treatment protocols and treat patients via collaborating physicians and health care providers using legal patient-specific FDA guidelines, including studies permitted by Institutional Review Boards, patient-specific stem cell clinical trials, and direct treatments using the patients own stem cells that are harvested and re-injected for therapeutic purposes.
Through Dr. Comellas leadership, she and her team have trained and certifiedmore than 700 physicians worldwide in adult stem cell therapy. (Source)
The interview below allows the energetic Dr. Kristin Comella to give a thorough and upbeat description of adult stem cell therapy.
Since the late 1990s, adult stem cells used therapeutically were not under the control of the FDA and the adult stem cell movement took off.
There were complaints from some MDs that the adult stem cell practice should be regulated by the FDA. The Panama College of Cell Science responded to those outcries with this statement:
The motive in opposing adult stem cell therapy is money. The big institutions want to keep federal funding of embryonic stem cell research at a high level with the promise that cures are just around the corner despite the fact that embryonic stem cells will never be useful in any way for patient treatment because they immediately cause tumors when transplanted. (Source)
Adult stem cell therapy is an autologous treatment method. The stem cells are not lab-created. They are only isolated and purified after extracting them from the patient being treated. Injecting them back into that patient powers up the bodys own healing mechanism to overcome chronic ailments.
The FDA didnt and shouldnt have anything to do with regulating stem cells from ones own body. That situation has recently been arbitrarily and suddenly changed.
Around 2014, the FDA started tweaking their guidance rules for stem cell therapy with the purpose of getting new rules made into laws through Congress that could be interpreted according to FDA whims and enforced arbitrarily. Their agenda is to consider adult stem cells as FDA-regulated drugs.
During our phone conversation, Dr. Comella explained how the FDA ignored testimonies from adult stem cell practitioners during their 2015 public hearings regarding new guideline proposals. Then they arranged to create new rules behind closed door meetings that included pharmaceutical industry allies and insiders.
The result was that by 2017, the FDAs hands-off policy with adult stem cell therapy came to a sudden halt after years of highly successful stem cell practice.
By 2018, the FDA got nastier with the the most influential clinician on the subject of adult stem cell therapy as its target. The FDA started doing inspections of Dr. Comellas South Florida clinic that aredesigned for labs that manufacture drugs.
The standards for hospitals and clinics are not as strict as drug manufacturers. Those inspections were inappropriate for a clinic. But those inspectionsmade it easier to create damaging reports.
When the inspectors came by, they demanded to go into rooms while treatments were taking place with semi-nude or nude patients, which Dr. Comella prohibited. The inspectors also demanded to view patient medical records. She allowed that after redacting their names on the copies she gave them.
For her actions to protect patients privacy, inspectors allegedly cited Dr. Comella for resisting and obstructing FDA inspections.
Soon after the inspections, the FDA served Dr. Comella with a lawsuit for practicing medicine with unapproved drugs. The drugs were only those stem cell solutions drawn from patients to be used on them.
The FDA has allegedly offered to drop the lawsuit if Dr. Comella signed an agreement to stop doing adult stem cell therapy and no longer promote it.
She refused. She said she has witnessed people leave their wheelchairs for good from this therapy. The trial is set for a Federal Court hearing beginning June 2019, in Miami, Florida.
If Dr. Comella loses this court case, adult stem cell therapy in the USA may be forced out of the country and only be available to those who can affordmedical tourism.
Published on March 11, 2019
- 13 promising Covid-19 treatments emerging from Israel - The Yucatan Times - July 10th, 2020
- Stem Cell Manufacturing Market Outlook, Opportunity and Demand Analysis, Forecast 2020-2027|-Merck Group, Becton, Dickinson And Company. Holostem... - July 10th, 2020
- Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional... - July 10th, 2020
- Cellular Reprogramming Tools Market Key Players, Industry Overview, Application and Analysis to 2020-2026 - Cole of Duty - July 2nd, 2020
- Growth in Sales of Cell Banking Outsourcing Market to Push Revenue Growth in the Market - 3rd Watch News - July 2nd, 2020
- COVID-19: Plasma therapy vs stem cell therapy, what's the difference? - Gulf News - June 29th, 2020
- Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma - Science Advances - June 29th, 2020
- Novel coronavirus infection might trigger type-1 diabetes - The Hindu - June 29th, 2020
- Stem Cells Market Analysis Growth Opportunities and Demand Drives by 2016 to 2028 - 3rd Watch News - June 28th, 2020
- BrainStorm Cell Therapeutics to Join the Russell 2000 Index and Russell 3000 Index - Yahoo Finance - June 26th, 2020
- COVID-19 impact: Stem Cells Market to Witness Steady Expansion During 2019-2026 - Personal Injury Bureau UK - June 26th, 2020
- Nuclear softening expedites interstitial cell migration in fibrous networks and dense connective tissues - Science Advances - June 20th, 2020
- Global Stem Cell Market Study and Forecast 2020-2025: Oncology Disorders Expected to Exhibit the Fastest Growth Rate - ResearchAndMarkets.com -... - June 20th, 2020
- EHA25Virtual: Adult Patients With Sickle Cell Disease May Be at Increased Risk of Adverse Outcomes From COVID-19 - Yahoo Finance - June 16th, 2020
- Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly... - June 16th, 2020
- Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress - BioSpace - June 12th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with Multi... - June 12th, 2020
- Having a good level of vitamin D may reduce the risk of certain cancers - Yahoo Singapore News - June 11th, 2020
- Major skin cancer research study to begin at The Hormel Institute - Austin Daily Herald - Austin Herald - June 11th, 2020
- Transforming the spleen into a liver-like organ in vivo - Science Advances - June 11th, 2020
- Creating hairy human skin: Not as easy as you think - Science Codex - June 7th, 2020
- Cellular Reprogramming Tools Market Research Key Players, Industry Overview and forecasts to | 2026 - Weekly Wall - June 5th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with... - June 5th, 2020
- Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia - Business Wire - June 5th, 2020
- Global Stem Cell Characterization Kits Market : Analysis and In-depth Study on Market Size Trends, Emerging Growth Factors and Forecasts to 2029 - The... - June 3rd, 2020
- Mesoblast (NASDAQ:MESO) Stock Rating Lowered by Zacks Investment Research - MarketBeat - June 3rd, 2020
- Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News - June 2nd, 2020
- AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other... - June 2nd, 2020
- Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- What It's Like to Grow a 'Mini-Brain' From Your Own Cells - Discover Magazine - May 25th, 2020
- Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry... - May 25th, 2020
- Newborn in Japan receives first treatment with liver STEM cells - ZME Science - May 23rd, 2020
- Adult Stem Cells Market with Coronavirus (Covid-19) Impact Analysis | Industry Strong Development By Major Eminent Players, New Innovations, Key... - May 16th, 2020
- Stem Cell and Regenerative Therapy Market Covid-19 Impact Analysis, Size, Share & Trends Analysis Report by Component, By Enterprise Size, By End... - May 16th, 2020
- The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer - Science Advances - May 16th, 2020
- Stem Cells Market Market Developments and Analysis (impact of Covid-19) 2020-2026 - Herald Writeup - May 15th, 2020
- Takeda Pharmaceutical : China announces ADCETRIS (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas -... - May 15th, 2020
- New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European... - May 14th, 2020
- Dlp-mediated Hh and Wnt signaling interdependence is critical in the niche for germline stem cell progeny differentiation - Science Advances - May 14th, 2020
- Little Skates Could Hold the Key to Cartilage Therapy in Humans - Technology Networks - May 14th, 2020
- Strides in Medical Tourism Market Key Driver of Low-cost Patient Care in Globalized Healthcare Systems, Notes TMR - PR Newswire UK - May 14th, 2020
- Australia's Mesoblast raises $90M to scale up stem cell therapy manufacturing to treat COVID-19 ARDS - BioWorld Online - May 14th, 2020
- CTX001 for Treatment of Sickle Cell Disease and Other Blood Disorders - Sickle Cell Anemia News - May 14th, 2020
- Stem cells therapy A prospective treatment against coronavirus? - Daily Excelsior - May 14th, 2020
- Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings - Targeted Oncology - May 13th, 2020
- BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - Yahoo Finance - May 13th, 2020
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the... - May 13th, 2020
- Study: Want to lose weight? Get rid of that pesky nose - The Big Smoke Australia - May 13th, 2020
- Rituximab Offers No Extra Benefit to Induction Chemo in ALL - Medscape - May 9th, 2020
- ROCKET PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - May 9th, 2020
- BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn for The European Union - BioSpace - May 7th, 2020
- Stem Cells Market 2020 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and... - May 7th, 2020
- Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs - The Sun - May 7th, 2020
- Roeland Nusse receives Canada's Gairdner International Award | The Dish - Stanford University News - May 7th, 2020
- Broad Foundation brings together stem cell scientists, engineers and physicians at University of Southern - Mirage News - May 7th, 2020
- Schizophrenia drug points to improved brain cancer radiation therapy - New Atlas - May 7th, 2020
- Scientists finally explained one of the strangest coronavirus symptoms - BGR - May 5th, 2020
- What Do New Neurons in the Brains of Adults Actually Do? - The Scientist - May 5th, 2020
- Therapy Harnesses Immune System to Slow Progression of DIPG Brain Tumors - University of Michigan Health System News - May 5th, 2020
- Acute Myeloid Leukemia Therapeutics Market Latest Innovations, Drivers and Industry Key Events During Forecast 2017 2025 - Jewish Life News - May 5th, 2020
- Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M - Xconomy - May 4th, 2020
- Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan... - May 4th, 2020
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... - May 4th, 2020
- Stem cell therapy shows 83% survival of Coronavirus patients on ventilators - International Business Times, Singapore Edition - April 26th, 2020
- There's no treatment for COVID-19, but Virginia researchers are ramping up clinical trials to try to find one - Richmond.com - April 26th, 2020
- Newest American Academy of Arts and Sciences members | Stanford News - Stanford University News - April 26th, 2020
- 'I Will Not Kill Children to Live' - Church Militant - April 24th, 2020
- Morning Update: Canadas data gaps are hurting our ability to fight the pandemic - The Globe and Mail - April 24th, 2020
- Adult Stem Cell - an overview | ScienceDirect Topics - April 12th, 2020
- Coronavirus updates: Masks required for take out; N.J. hospitalizations to peak within 3 weeks; Stimulus paym - NJ.com - April 12th, 2020
- 4 ways to promote neurogenesis in your brain - Big Think - April 9th, 2020
- Funding roundup: At-home medical exams and a Parkinson's treatment - MedCity News - April 9th, 2020
- Moderna: A $12 Billion Brand Built On Hope And mRNA - Seeking Alpha - April 9th, 2020
- BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority - Yahoo Finance - April 3rd, 2020
- Post-Remission Therapy For AML: Allogeneic Stem-Cell Transplant - SurvivorNet - April 3rd, 2020
- Intermittent fasting might boost the creation of new neurons in a key brain structure - PsyPost - April 3rd, 2020
- 4 relationship problems that can be linked back to early childhood - Big Think - March 28th, 2020
- Scientists Have 'Reset' The Cellular Age Of Cells Taken From A 114-Year-Old Woman - IFLScience - March 26th, 2020
- The Answer to the Coronavirus Is More Abortion? - Townhall - March 24th, 2020